Structured exercise interventions and survival outcomes in patients with cancer: systematic review and meta-analysis of randomised controlled trials.

Br J Sports MedSep 24, 2026 (epub)
Clinical ResearchOncology (Medical)

Chih-Chen Tzang, Chiao-An Luo, Vicky Fu-Hsuan Kuo et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of structured exercise interventions on survival outcomes in cancer patients. Analyzing data from 21 randomized controlled trials, the study found that structured exercise significantly improved overall survival (HR 0.77), disease-free survival (HR 0.83), reduced all-cause mortality (RR 0.82), and cancer-specific mortality (RR 0.74).

Key findings

  • Overall survival improved significantly with structured exercise (HR 0.77; 95% CI 0.65 to 0.92).
  • Disease-free survival showed significant enhancement (HR 0.83; 95% CI 0.72 to 0.95).
  • All-cause mortality was reduced (RR 0.82; 95% CI 0.70 to 0.97).
  • Cancer-specific mortality decreased significantly (RR 0.74; 95% CI 0.57 to 0.96).

Why it matters

The findings suggest that structured exercise may play a crucial role in improving survival outcomes for cancer patients, highlighting its potential as an important component of oncological care beyond quality of life enhancement.

Source

PubMed · PMID 42744658

Published in Br J Sports Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.